Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Perrigo Shareholder Lawsuits Claim Joining Mylan Was A Better Idea

Executive Summary

Two complaints seeking compensation for Perrigo shareholders and four motions seeking lead plaintiff designations in the litigation have been filed in US district court. Both target Perrigo's fundamental argument against Mylan's takeover bid in 2015, that the company would be stronger continuing on its own.

You may also be interested in...



Perrigo Haunted By Mylan Rejection As Securities Fraud Complaints Mount

Securities fraud complaint filed by Nationwide Mutual Funds alleges firm misled investors to fend off Mylan hostile takeover in 2015 before its share price began plummeting. It is latest of similar complaints filed against Perrigo in New Jersey federal court.

Perrigo Haunted By Mylan Rejection As Securities Fraud Complaints Mount

Securities fraud complaint filed by Nationwide Mutual Funds alleges firm misled investors to fend off Mylan hostile takeover in 2015 before its share price began plummeting. It is latest of similar complaints filed against Perrigo in New Jersey federal court.

Perrigo Starts Branded Consumer Product Rescue Mission In Belgium

Perrigo is restructuring its OTC drug and nutritional product businesses in Belgium – Omega Pharma Belgium NV, Etixx NV and Biover NV – and expects changes will eliminate between 45 and 80 jobs.

Related Content

Topics

Related Companies

Latest News
UsernamePublicRestriction

Register

PS118821

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel